NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Individuals Who Provided Content Development and/or Authorship Assistance

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Sharon Spencer, MD, Panel Vice Chair
Ellie Maghami, MD, Panel Member
Jennifer L. Burns, BS, Manager, Guidelines Support, NCCN
Susan D. Darlow, PhD, Oncology Scientist/Senior Medical Writer, NCCN

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
David Pfister, MD, Panel Chair, grant/research support from Bristol-Myers Squibb Company, Genentech, Inc., Cue Biopharma, Hookipa Pharma Inc., Kura Oncology, Inc., Merck & Co., Inc., and Novartis Pharmaceuticals Corporation; and data safety monitoring committee member for Boehringer-Ingelheim, GmbH.
Douglas Adkins, MD, Panel Member, grant/research support from AstraZeneca Pharmaceuticals LP, BeiGene, Blueprint Medicines, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai Inc., Eli Lilly and Company, Exelixis Inc., Gilead Sciences, Inc., Hookipa Pharma Inc., Kura Oncology, Inc., Merck & Co., Inc., Adlai-Nortye, CUE Biosciences, Debio, Epizme, Isa Therapeutics, Oncolys, Rubius, Vaccinex, Pfizer Inc., and Roche Laboratories, Inc.; and consulting fees from Blueprint Medicines, Boehringer Ingelheim GmbH, Eisai Inc., Exelixis Inc., Kura Oncology, Inc., Merck & Co., Inc., Coherus Biosciences, CUE Biosciences, Immunitas, Targimmune, Vaccinex, and Xilio.
David M. Brizel, MD, Panel Member, royalty income from UpToDate.
Jimmy J. Caudell, MD, PhD, Panel Member, grant/research support from Varian Medical Systems, Inc.; and scientific advisor for Galera.
A. Dimitrios Colevas, MD, Panel Member, grant/research support from AbbVie, Inc., Atara Biotherapeutics, BioNTech, Cue, Cullinan Oncology, Exelixis, Inc., Gilead Sciences, Inc., Innate Pharma, Replimune Group, and Tessa Therapeutics; consulting fees from Grand Rounds and PDS Biotech; and scientific advisor for Gilead Sciences, Inc.
Maura L. Gillison, MD, PhD, Panel Member, grant/research support from Bristol-Myers Squibb Company, Gilead Sciences, Inc., and Kura Oncology, Inc.; and consulting fees from Bayer HealthCare, Bristol-Myers Squibb Company, Eisai Inc., EMD Serono, Ipsen, Merck & Co., Inc., Nektar Therapeutics, and Roche Laboratories, Inc.
Cristina P. Rodriguez, MD, Panel Member, grant/research support from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Kura Oncology, Inc., Merck & Co., Inc., Ayala, and Cue; and scientific advisor for Coherus and Cue.
David Sher, MD, MPH, Panel Member, grant/research support from Varian Medical Systems, Inc.
Gregory Weinstein, MD, Panel Member, royalty income from Olympus Corporation.
Francis Worden, MD, Panel Member, honoraria from Bayer HealthCare; and scientific advisor for Eisai Inc., Exelixis Inc., Merck & Co., Inc.

View all of the conflicts of interest for the NCCN Guidelines panel

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.